AMARIN CORP: Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions

Amarin Corp issued the following announcement on  April 12.

An a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, is supporting the presentation of three accepted scientific presentations at the National Lipid Association (NLA) Scientific Sessions in Las Vegas, NV, April 26-29, 2018.

"Amarin is proud to be working with partners like Optum Healthcare, the NHANES database and other experts to better determine the prevalence and potential health impact of persistent high triglycerides," said Craig B. Granowitz, M.D., Ph.D., senior vice president and chief medical officer of Amarin. "As this medical condition impacts tens of millions of Americans, determining the scope and potential consequences of this clinical condition is important for setting national healthcare priorities."

Data to be presented include:

Poster Presentations

Prevalence and Predictors of Residual Hypertriglyceridemia According to Statin Use in US Adults

-- Wenjun Fan, Sephy Philip, Craig Granowitz, Peter P. Toth, Nathan D. Wong

Knowledge, Perceptions, and Patterns of "Fish Oil" Use in Cardiac Patients

-- Daniel E. Hilleman, Robyn Teply, Kathleen A. Packard

Oral Presentation

High Triglycerides and ASCVD Are Significant Predictors of Major CV Events and Increased Costs in Statin-Treated Patients: Real-World Analysis

-- Peter P. Toth, Craig Granowitz, Michael Hull, Sephy Philip

Original source: http://investor.amarincorp.com/releasedetail.cfm?ReleaseID=1063708

Want to get notified whenever we write about Amarin Corp ?
Next time we write about Amarin Corp, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Amarin Corp 1430 Route 206 Bedminster, NJ 07921